University Hospitals Birmingham NHS Foundation Trust

Loading results...
View full results list

Reports

Status

Drug name

NICE TAs

Comments

Status: Red

Dronedarone tablets

TA197 - Dronedarone for the treatment of non-permanent atrial fibrillation

Status: Red

Dupilumab

Status: Red

Durvalumab

TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA 1030 Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer

Status: Grey

Durvalumab

NICE TA 1099 Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

Status: Red

Eculizumab (Bekemv®)

NICE HST1 Eculizumab for treating atypical haemolytic uraemic syndrome

Status: Green

Edoxaban

Second choice following diagnosis of AF- use in line with NICE.

Status: Amber

Edoxaban#Amber

Specialist initiation - For the treatment and secondary prevention of DVT and/or PE - use in line with NICE and supported by RICaD

Anticoagulant Initiation Flowchart for Anticoagulation in Atrial Fibrillation

Status: Red

Efanesoctocog alfa (ALTUVOCT®)

NICE TA 1051Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over

Status: Red

Elafibranor (Iqirvo®)

NICE TA1016 Elafibranor for previously treated primary biliary cholangitis

Status: Red

Elranatamab (Elrexfio®)

NICE TA 1023 Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Building healthier lives